* Gene-targeted therapies show potential to address these limitations, but challenges in preclinical and clinical testing, as well as delivery methods, need to be resolved first.
* Developing better preclinical models, validated assays to measure specific protein activities, and educating patients and clinicians about the risks and benefits of these therapies is crucial for future advancements.